Key Takeaways
- JPMorgan initiated coverage on HIMS with a Neutral rating and $32 price objective, representing approximately 16% potential gain from present trading levels
- Analysts highlight concerns over the company’s transition from compounded GLP-1 medications to FDA-approved branded alternatives such as Wegovy
- Through its collaboration with Novo Nordisk, Hims processed more than 125,000 Wegovy orders within the initial six-week period
- Second quarter revenues reached $753.21 million, reflecting a 38.2% annual increase, though the company significantly underperformed on profitability with a $0.37 per share loss versus the anticipated $0.05 loss
- Additional challenges include an FTC complaint and ongoing securities litigation that create uncertainty for investors
HIMS started Friday’s session at $27.52, substantially below its 52-week peak of $65.30. The newly assigned $32 price objective from JPMorgan suggests measured optimism rather than strong bullish sentiment. Shares declined approximately 1% during trading.
Hims & Hers Health, Inc., HIMS
Bryan Smilek, analyst at JPMorgan, launched coverage with a Neutral designation, acknowledging the telehealth company’s impressive expansion while highlighting substantial operational uncertainties connected to its GLP-1 strategy transformation.
In March, Hims revealed plans to discontinue marketing compounded GLP-1 products, committing instead to exclusively offering branded, FDA-sanctioned treatments. This strategic shift introduces considerable uncertainty. Revenue from compounded formulations continues declining while branded product volume remains in early growth stages.
Smilek forecasts 2026 GLP-1 revenue reaching $1.1 billion, marking a 46% annual climb, fueled by the Novo Nordisk collaboration. His analysis suggests the Wegovy arrangement should adequately compensate for revenue losses from discontinued compounded offerings.
The partnership with Novo launched strongly. Hims completed over 125,000 Wegovy deliveries during only the opening six weeks of availability.
JPMorgan projects substantial expansion potential for the GLP-1 sector. The firm estimates cash-paying U.S. GLP-1 consumers could expand from approximately 2.8 million currently to exceeding 8 million by decade’s end.
Company management targets 2030 revenue surpassing $6.5 billion alongside adjusted EBITDA above $1.3 billion, supported by global market penetration and category diversification including peptide therapies.
Financial Performance Analysis
Recent quarterly results presented a contradictory narrative. Revenue totaling $753.21 million surpassed the $698.90 million analyst consensus and represented 38.2% year-over-year growth.
However, profitability metrics proved disappointing. The firm posted a $0.37 per share loss, dramatically worse than the projected $0.05 loss. This substantial variance concerned market participants.
Shares declined 7.7% following the earnings announcement, per Zacks data, demonstrating investor sensitivity to profitability shortfalls.
Regulatory and Legal Challenges
Compounding the earnings disappointment, HIMS confronts two significant legal matters. The FTC filed a complaint asserting deceptive and improper privacy handling. Additionally, a securities class action encompasses investors holding shares between August 2025 and July 2026, with November 2, 2026 established as the lead-plaintiff filing deadline.
While neither proceeding has reached judicial determination, both introduce additional uncertainty into the investment thesis.
Wall Street consensus sentiment registers as Hold. Among 16 analysts tracked by MarketBeat, 12 recommend Hold, three advise Buy, and one suggests Sell. The mean price target stands at $32.43.
JPMorgan’s Smilek indicates he requires evidence that the branded GLP-1 transition maintains momentum, emerging therapeutic areas demonstrate sustainable growth, and profit margins improve before adopting a more optimistic position on shares.
Corporate insiders have reduced holdings. During the past 90 days, insiders divested 190,227 shares valued at more than $6.1 million.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
